Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Patients With Advanced Parkinson's Disease

Change in Disease-Specific Caregiver Burden in Arm A

Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in disease-specific caregiver burden as measured by the Modified Caregiver Strain Index (MCSI) for PD with a total score range from 0 to 26.

Time frame: Baseline visit (Enrollment) to month 36

Change in the Duration of Dyskinesia in Arm A

Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in duration of dyskinesia as reported by the patient for the day prior to the clinical visit

Time frame: Baseline visit (Enrollment) to month 36

Change in Disease-Specific Sleep Quality in Arm A

Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in disease-specific sleep quality as measured by Parkinson's Disease Sleep Scale-2 (PDSS-2) with a total score range from 0 to 60.

Time frame: Baseline visit (Enrollment) to month 36

Change in Tremor Severity in Arm A

Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in tremor severity as measured by UPDRS Part III, item 20 (Tremor at Rest) with a total score range of 0 to 20.

Time frame: Baseline visit (Enrollment) to month 36

Change in Motor Function in Arm A

Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in motor function as measured by UPDRS, Part III (Motor Examination) with a total score range of 0 to 108.

Time frame: Baseline visit (Enrollment) to month 36

Change in Generic Quality of Life in Arm A

Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in generic quality of life as measured by EuroQoL-5 Dimensions Quality of Life Questionnaire (EQ-5D). This assessment contains a health state descriptive part with five items scored from 1 to 3.

Time frame: Baseline visit (Enrollment) to month 36

Change in Dyskinesia Severity in Arm A

Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in dyskinesia severity as measured by Unified Dyskinesia Rating Scale (UDysRS) with a total score range from 0 to 104.

Time frame: Baseline visit (Enrollment) to month 36

Change in Overall Clinical Impression of Disease Severity in Arm A

Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in overall clinical impression of disease severity as measured by Clinical Impression of Severity Index for Parkinson's Disease (CISI-PD) obtained by adding four domain scores with a total score range from 0 to 24.

Time frame: Baseline visit (Enrollment) to month 36

Change in Disease-Specific Quality of Life in Arm A

Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in disease-specific quality of life (QoL) as measured by Parkinson's Disease Questionnaire 8 (PDQ-8) summary index range from 0 to 100.

Time frame: Baseline visit (Enrollment) to month 36

Change in OFF Time Duration in Arm A

Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in OFF time duration as measured by UPDRS Part IV (Motor Fluctuations), item 39, with a total score range of 0 to 4.

Time frame: Baseline visit (Enrollment) to month 36

Change in Non-Motor Symptoms in Arm A

Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in non-motor symptoms as measured by Non-Motor Symptoms Scale (NMSS) with a total score range from 0 to 360.

Time frame: Baseline visit (Enrollment) to month 36

Change in Healthcare Resource Utilization in Arm A

Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in healthcare resource utilization as measured by the Healthcare Resource Utilization Questionnaire (HCRU).

Time frame: Baseline visit (Enrollment) to month 36

Change in Daytime Sleepiness in Arm A

Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in daytime sleepiness as measured by Epworth Sleepiness Scale (ESS) with a total score range from 0 to 24.

Time frame: Baseline visit (Enrollment) to month 36

Change in Activities of Daily Living in Arm A

Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in Activities of Daily Living as measured by Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activity of Daily Living) with a total score range of 0 to 52.

Time frame: Baseline visit (Enrollment) to month 36

Change in Complications of Therapy in Arm A

Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in Complications of Therapy (dyskinesia duration, disability, pain and early morning dystonia) as measured by UPDRS Part IV (Complications of Therapy), items 32 (individual score 0 to 4), 33 (individual score 0 to 4), 34 (individual score 0 to 4), 35 (individual score 0 to 1) and total score range of 0 to 13.

Time frame: Baseline visit (Enrollment) to month 36

Correlation of non-motor and motor improvements with Quality of Life improvements in Arm A

Assess the correlation of non-motor and motor improvements with the improvement in the Quality of Life (QOL).

Time frame: Baseline visit (Enrollment) to month 36

Correlation between duration of OFF time measured by UPDRS IV and duration of bradykinesia score above target in Arm B

Assess the correlation between duration of OFF time measured by UPDRS IV item 39 and duration of bradykinesia score above target between 09:00 - 18:00 and for the full 24 hours per day measured by PKG

Time frame: Baseline visit (Enrollment) to month 6

Correlation between duration of OFF time measured by patient with PD Diary and average bradykinesia score in Arm B

Assess the correlation between duration of OFF time measured by patient with PD Diary both per full 24 hours and for the time period of 09:00 - 18:00 and average bradykinesia score measured by PKG

Time frame: Baseline visit (Enrollment) to month 6

Correlation between duration of bradykinesia score above target and average bradykinesia score in Arm B

Assess the correlation between duration of bradykinesia score above target between 09:00 - 18:00 and for the full 24 hours per day measured by PKG and average bradykinesia score measured by PKG

Time frame: Baseline visit (Enrollment) to month 6

Correlation between duration of OFF time measured by patient with PD Diary and duration of bradykinesia score above target in Arm B

Assess the correlation between duration of OFF time measured by patient with PD Diary both per full 24 hours and for the time period of 09:00 - 18:00 and duration of bradykinesia score above target between 09:00 - 18:00 and for the full 24 hours per day measured by PKG

Time frame: Baseline visit (Enrollment) to month 6

Correlation between duration of OFF time measured by UPDRS IV and average bradykinesia score in Arm B

Assess the correlation between duration of OFF time measured by UPDRS IV item 39 and average bradykinesia score measured by PKG

Time frame: Baseline visit (Enrollment) to month 6

Correlation between duration of dyskinesia and Unified Dyskinesia Rating Scale (UDysRS) in Arm B

Pairwise correlation between duration of dyskinesia both per full 24 hours and 09:00 - 18:00 (based on UPDRS IV, PD diary and dyskinesia score measured by PKG) and UDysRS will be evaluated

Time frame: Baseline visit (Enrollment) to month 6

Severity of dyskinesia in Arm B

Severity of dyskinesia (item 33 score of UPDRS IV, UDysRS total score or the PKG-based dyskinesia score and the pairwise correlation between these will be evaluated

Time frame: Baseline visit (Enrollment) to month 6

Motor symptoms in Arm B

Motor symptoms measured by UPDRS III in ON state and correlation with PKG-based bradykinesia score will be evaluated

Time frame: Baseline visit (Enrollment) to month 6

Severity of tremor in Arm B

Severity of tremor measured by item 20 of UPDRS III in ON state and PKG-based tremor score and correlation between both will be evaluated

Time frame: Baseline visit (Enrollment) to month 6

Activities of Daily Living (ADL) in Arm B

ADL measured by UPDRS II in ON state and correlation with and PKG-based fluctuation/dyskinesia score and bradykinesia score will be evaluated

Time frame: Baseline visit (Enrollment) to month 6

Sleep in Arm B

Sleep as measured by PDSS-2, sleep/fatigue subdomain of NMSS, duration of sleep based on PD Diary or PKG-based night-time total sleep and pairwise correlation between these will be evaluated

Time frame: Baseline visit (Enrollment) to month 6

Daytime sleepiness in Arm B

Daytime sleepiness as measured by PKG-based percent of time asleep in the day time and the Epworth Sleepiness Scale and the correlation between these will be evaluated

Time frame: Baseline visit (Enrollment) to month 6

Quality of Life (QoL) in Arm B

QoL as measured by PDQ-8 and the correlation with PKG-based fluctuation/dyskinesia and bradykinesia scores will be evaluated

Time frame: Baseline visit (Enrollment) to month 6